Acorda Therapeutics Inc. (ACOR) announced Monday morning that data from a Phase 2 study of AMPYRA Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.
Acorda Therapeutics gapped up and rose sharply during the first 45 minutes of trade Monday, before settling into a range. The stock closed up by 3.98 at $35.50 on strong volume and broke out to a new high for the year.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org